Nevirapine Plus Zidovudine to Prevent Perinatal HIV in Thailand
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the efficacy of a single dose of the drug nevirapine
(NVP) given to pregnant women at onset of labor and to their infant 48-72 hours after birth
in addition to standard oral zidovudine (ZDV or AZT) prophylaxis for the prevention of
mother-to-child transmission of HIV-1.
Phase:
Phase 3
Details
Lead Sponsor:
Institut de Recherche pour le Developpement
Collaborators:
ANRS, Emerging Infectious Diseases Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) Harvard School of Public Health Harvard School of Public Health (HSPH)